Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 5897.085 | 0.9836 | 0.9734 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 5897.085 | 1.0160 | 1.0258 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 5897.085 | 0.9775 | 0.9636 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 5897.085 | 1.0044 | 1.0072 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 5897.085 | 0.9814 | 0.9699 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 5897.085 | 0.4318 | 0.0156 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 5897.085 | 0.0957 | -0.6991 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 5897.085 | 0.0573 | -0.8011 | 1.2392 | |
| 184B5 | NM | Basal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 5897.085 | 0.0205 | -0.9132 | 1.2392 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 5898.085 | 0.9196 | 0.7757 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 5898.085 | 0.8775 | 0.6616 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 5898.085 | 0.9608 | 0.8896 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 5898.085 | 0.9620 | 0.8929 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 5898.085 | 0.9778 | 0.9372 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 5898.085 | 0.9063 | 0.7394 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 5898.085 | 0.9411 | 0.8350 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 5898.085 | 0.7544 | 0.3407 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 5898.085 | 0.0245 | -0.9896 | 0.7048 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 5899.084 | 0.9863 | 0.9754 | 1.1144 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 5899.084 | 0.9693 | 0.9449 | 1.1144 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 5899.084 | 0.9920 | 0.9856 | 1.1144 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 5899.084 | 0.9434 | 0.8981 | 1.1144 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 5899.084 | 0.9927 | 0.9869 | 1.1144 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 5899.084 | 0.9084 | 0.8347 | 1.1144 | |
| 600MPE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 5899.084 | 0.6899 | 0.4333 | 1.1144 |